Plasmin-dependent thrombolytic agents are potentially prothrombotic and proinflammatory. Alfimeprase, a zinc-containing metalloproteinase, degrades fibrin directly and achieves thrombolysis independent of plasmin formation. This study examines the hypothesis that thrombolysis in the absence of plasmin generation results in improved myocardial salvage on reperfusion. The thrombolytic effects of ...

In Thailand, 2005, the mortality rate of stroke was 24.3 per 100,000 populations and since then it has continuously increased. The prevalence of stroke increased from 216.6 to 307.9 in 2008 to 2010. Diabetes, hypertension and hyperlipidaemia are the root cause of stroke and myocardial infarction. To prevent stroke is to prevent complication, and in order to do so, it needs the implementation of...

The thrombolytic activity of a novel modified tissue-type plasminogen activator (t-PA) (E6010) was examined in a canine model with copper coil-induced femoral artery thrombus. This model, in which thrombolytic activity can be easily and directly quantified by determining changes in thrombus weight, should be useful for comparing the activities of various thrombolytic agents. Using this model, t...

OBJECTIVES The aim of this study was to evaluate the consequences, measured as mortality and in-hospital stroke, of the use of thrombolytic therapy among patients with acute myocardial infarction (AMI), who do not fulfill accepted criteria or who have contraindications to thrombolytic therapy (i.e., overutilization) and among patients who are withheld thrombolytic treatment despite fulfilling i...

Accepted 15 September 1995 In 1980, De Wood et al first reported angiographic evidence of a high incidence of totally occluded or critically stenosed infarct-related arteries in the early hours of acute myocardial infarction.' Such findings prompted the use of intracoronary and later intravenous streptokinase therapy. It is now well established that after acute myocardial infarction, the earlie...

The CAEP Stroke Practice Committee was convened in the spring of 2013 to revisit the 2001 policy statement on the use of thrombolytic therapy in acute ischemic stroke. The terms of reference of the panel were developed to include national representation from urban academic centres as well as community and rural centres from all regions of the country. Membership was determined by attracting rec...

If thrombolytic treatment represents the second major advance in the management of patients with acute coronary thrombosis, will it gain more widespread acceptance in prehospital treatment than the other major advance, defibrillation? For more than 20 years it has been clear that almost half of the early deaths from myocardial infarction occur within the first two hours, and yet we have failed ...

background: we sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely heberkinasa (heberbiotec, havana, cuba) and streptase (aventis behring gmbh, marburg, germany). methods: we conducted a double-blind randomized clinical trial to compare the two streptokinase formulations, i.e. heberkinasa (hbk) or streptase (stp), in patients...

BACKGROUND AND PURPOSE Thrombolysis therapy using tissue-type plasminogen activator (t-PA) is occasionally accompanied by harmful outcomes, including intracerebral hemorrhage. We have reported that Stachybotrys microspora triprenyl phenol-7 (SMTP-7), a candidate thrombolytic drug, has excellent therapeutic effect on cerebral infarction in embolic stroke model in mice; however, little is known r...

The CAEP Stroke Practice Committee was convened in the spring of 2013 to revisit the 2001 policy statement on the use of thrombolytic therapy in acute ischemic stroke. The terms of reference of the panel were developed to include national representation from urban academic centres as well as community and rural centres from all regions of the country. Membership was determined by attracting rec...